

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Anti-Human CD52 (Alemtuzumab) - Fc Muted™ HRP

RRID:AB_2893945

Type: Antibody

Proper Citation

Leinco Technologies Cat# LT207, RRID:AB_2893945

Antibody Information

URL: http://antibodyregistry.org/AB_2893945

Proper Citation: Leinco Technologies Cat# LT207, RRID:AB_2893945

Target Antigen: CD52

Host Organism: human

Clonality: recombinant monoclonal

Comments: Applications: ELISA, FA, FC

Info: This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only.

Antibody Name: Anti-Human CD52 (Alemtuzumab) - Fc Muted™ HRP

Description: This recombinant monoclonal targets CD52

Target Organism: Human, Rhesus Monkey, Cynomolgus Monkey

Clone ID: clone: Campath-1H

Antibody ID: AB_2893945

Vendor: Leinco Technologies

Catalog Number: LT207

Record Creation Time: 20231110T031706+0000

Record Last Update: 20260828T230346+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Human CD52 (Alemtuzumab) - Fc Muted™ HRP.

No alerts have been found for Anti-Human CD52 (Alemtuzumab) - Fc Muted™ HRP.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang G, et al. (2026) VGLL4 promotes hepatocellular carcinoma progression via the Wnt/ β -catenin pathway. Tissue & cell, 100, 103391.